HIV Clinical Trial
Official title:
Use of EndoPAT for Measurements of Endothelial Dysfunction in HIV Infected Children and Healthy Controls
Our objective is to determine whether HIV infected youth have higher level of endothelial dysfunction, as measured by Peripheral Arterial Tonometry, when compared to age matched healthy controls. The investigators also aim to gather preliminary data on whether endothelial Peripheral Arterial Tonometry (endoPAT) measurements of endothelial dysfunction are independently associated with HIV and antiretroviral factors, and with markers of inflammation and traditional cardiovascular disease risk.
Study Objectives and Hypothesis Our objective is to determine whether HIV infected youth
have higher level of endothelial dysfunction, as measured by Peripheral Arterial Tonometry,
when compared to age matched healthy controls. We also aim to gather preliminary data on
whether endoPAT measurements of endothelial dysfunction are independently associated with
HIV and antiretroviral factors, and with markers of inflammation and traditional
cardiovascular disease risk.
Specific Aim 1:
To compare endothelial function, as measured by endoPAT, between HIV-infected youth and
matched healthy controls.
Hypothesis: HIV infected youths will have impaired endothelial function compared to age
matched healthy controls.
Specific Aim 2:
To determine risk factors of endothelial dysfunction by evaluating: 1) risk factors specific
to HIV such as disease stage, cluster of differentiation 4 (CD4) count, HIV viral load,
specific ART regimen, perinatally acquired versus behaviorally acquired infection; 2)
markers of cardiovascular disease risk such as smoking, lipid levels, insulin resistance; 3)
markers of inflammation and immune activation Hypothesis: Endothelial dysfunction will
correlate with advanced HIV disease stage, use of protease inhibitors and worse traditional
cardiovascular disease risk factors including lipids, insulin resistance, and smoking.
Specific Aim 3:
To assess whether endothelial function changes over a period of 24 weeks in HIV infected
youths and controls.
Hypothesis: Endothelial dysfunction will progress over time in HIV-infected children but not
in healthy controls.
Study Design This is a 24-week observational cohort study to gather preliminary data on the
prevalence and risk factors for endothelial dysfunction in HIV-infected youths. Children
enrolled will be between the ages of 8 and 30 years and either congenitally or behaviorally
infected with HIV, on continuous ART for at least 6 months and with HIV-1 RNA <1,000
copies/mL. We will also enroll an age- and gender-matched group of healthy controls. A total
of 50 HIV-infected children/young adults and 50 matched controls will be enrolled.
Evaluations will be performed at two time points: baseline and week 24. At both visits,
evaluations will be similar. We will collect demographic data and medical history including
date of birth, sex, gender, CD4 cell count nadir, past and current ART and non-ART
medication history, HIV stage based on the CDC guidelines, HIV diagnosis date and method of
HIV acquisition, alcohol, smoking and drug habits, as well as family history of
cardiovascular disease or diabetes. We will record clinical measurements including blood
pressure, physical examination abnormalities, waist and hip circumferences and tanner stage.
Subjects will undergo laboratory measurements of lipids levels and markers of insulin
resistance in a fasting state (>8 hrs fast except for water and medications), as well as
inflammation and immune activation markers (hsCRP, Interleukin 6 or IL-6, sCD14). HIV RNA
and CD4 cell count will be collected from clinical records. Plasma and serum will be stored
for possible future measurements of other inflammation and cardiovascular markers. We will
perform endothelial function measurements by PAT as recommended by the manufacturer.
Controls will be recruited from the community using Institutional Review Board
(IRB)-approved flyers, as uninfected siblings or relatives of the HIV-infected patients, or
from physician referrals.
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |